Leap therapeutics to present updated data from the distinguish study of dkn-01 plus tislelizumab and preclinical data in colorectal cancer models at the sitc annual meeting

55% orr, 73% dcr, and 7.7 month pfs in dkk1-high/pd-l1-high second-line gastric cancer patients dkn-01 also demonstrated preclinical tumor regression data in crc models supporting ongoing clinical trial cambridge, mass. , nov. 7, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the company will be presenting updated data from part b of the distinguish study evaluating dkn-01 in combination with tislelizumab, beigene's anti-pd-1 antibody, in second-line gastroesophageal adenocarcinoma (gea) cancer patients whose tumors express high levels of dkk1 (dkk1-high) at the society of immunotherapy for cancer (sitc) 37th annual meeting being held in boston, ma on november 8-12, 2022.
LPTX Ratings Summary
LPTX Quant Ranking